NEW YORK (360Dx) – CareFirst BlueCross BlueShield is looking to grow a new program aimed at helping diagnostic companies obtain insurance coverage for new tests.

The program, called HealthWorx, began operation in late August with a partnership with Exosome Diagnostics, a company developing exosome-based biofluid diagnostic tests. That partnership has already resulted in a completed 500-patient evidence development study of ExoDx's prostate cancer diagnostic, the ExoDx Prostate IntelliScore, or EPI Test, according to executives at CareFirst and ExoDx.